Iksuda Therapeutics is a biotechnology company focussed on the development of innovative, next generation Antibody Drug Conjugates (ADCs). Our approach, centred on our proprietary, highly specific, highly stable PermaLink® conjugation platform is to enhance antitumor activity whilst minimising payload de-drugging and the off-target effects of chemotherapy. We are developing a pipeline of precision conjugates to effectively and safely treat current unmet clinical need through combination of our highly stable conjugation platform with a range of highly potent, tissue specific, novel toxin payloads.